



SDI Review Form 1.6

Journal Name:	International Research Journal of Oncology
Manuscript Number:	Ms_IRJO_50404
Title of the Manuscript:	Organoids As a form of Modern Day Silver Lining In Blood Cancer
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<p>The authors have done some insights on therapeutic challenges of hematological malignancies with a special focus on immunomodulation by organoids, but certain questions are to be answered as follows</p> <p>Abstract</p> <p>Question 1—line 3—therapeutic resistance of tumor affected stem cells. Please specify which factor is responsible for this therapeutic resistance. State the differential features of tumor stem cells and normal stem cells in a table for a better understanding and also state how organoids overcome this resistance.</p> <p>Question 2-lines 7-9—lower success rate of organoids in vivo models. In this study, organoids modeling done both in vivo-vitro cell cultures. Is the success rate assessed in the recent modeling? State the comparison between the two with reasons for the lower success rate in vivo model.</p> <p>Question 3-lines 14-17—nano-sized in cell clustering of organoids and MRI scanning help to identify the tumor that won't respond to any conventional therapy. Please specify how they are identified.</p> <p>Line 42—Organoids as an anti oncogenic agent. Please specify the effectiveness of organoids in different types of blood cancer. Explain the immunomodulation induced by the organoids.</p> <p>Table 03—please specify the growth factors & inhibitors applied in organoid cell culture separately rather than as a mixed one in the same column.</p>	The manuscript has been modified



SDI Review Form 1.6

Minor REVISION comments		
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	